Improvements may be realized as a result of increased efficacy, greater safety or reduced
cost. One approach to increasing the efficacy of thrombolytic therapy has been the
development of new and improved thrombolytic agents. Direct manipulation of plasminogen
activators offers one such viable approach to enhance the benefits of thrombolytic therapy,
and tissue plasminogen activator (tPA), for example, has been re-engineered to enhance its
pharmacokinetic profile, reduce its susceptibility to inhibitors and increase its fibrin …